Warning: The NCBI web site requires JavaScript to function. more...
Ethnic differences in the adaptation rate of HIV gp120 from a vaccine trial.
Pérez-Losada M, Posada D, Arenas M, Jobes DV, Sinangil F, Berman PW, Crandall KA.
Retrovirology. 2009 Jul 15;6:67.
Related citations
HIV gp120 vaccine - VaxGen: AIDSVAX, AIDSVAX B/B, AIDSVAX B/E, HIV gp120 vaccine - Genentech, HIV gp120 vaccine AIDSVAX - VaxGen, HIV vaccine AIDSVAX - VaxGen.
Adis International Ltd.
Drugs R D. 2003;4(4):249-53.
Immunological and virological analyses of persons infected by human immunodeficiency virus type 1 while participating in trials of recombinant gp120 subunit vaccines.
Connor RI, Korber BT, Graham BS, Hahn BH, Ho DD, Walker BD, Neumann AU, Vermund SH, Mestecky J, Jackson S, Fenamore E, Cao Y, Gao F, Kalams S, Kunstman KJ, McDonald D, McWilliams N, Trkola A, Moore JP, Wolinsky SM.
J Virol. 1998 Feb;72(2):1552-76.
Phylodynamics of HIV-1 from a phase-III AIDS vaccine trial in North America.
Pérez-Losada M, Jobes DV, Sinangil F, Crandall KA, Posada D, Berman PW.
Mol Biol Evol. 2010 Feb;27(2):417-25. Epub 2009 Oct 28.
A phase 1/2 comparative vaccine trial of the safety and immunogenicity of a CRF01_AE (subtype E) candidate vaccine: ALVAC-HIV (vCP1521) prime with oligomeric gp160 (92TH023/LAI-DID) or bivalent gp120 (CM235/SF2) boost.
Thongcharoen P, Suriyanon V, Paris RM, Khamboonruang C, de Souza MS, Ratto-Kim S, Karnasuta C, Polonis VR, Baglyos L, Habib RE, Gurunathan S, Barnett S, Brown AE, Birx DL, McNeil JG, Kim JH; for the Thai AIDS Vaccine Evaluation Group.
J Acquir Immune Defic Syndr. 2007 Sep 1;46(1):48-55.
Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial.
Gilbert PB, Peterson ML, Follmann D, Hudgens MG, Francis DP, Gurwith M, Heyward WL, Jobes DV, Popovic V, Self SG, Sinangil F, Burke D, Berman PW.
J Infect Dis. 2005 Mar 1;191(5):666-77. Epub 2005 Jan 27.
Proliferative responses to human immunodeficiency virus type 1 (HIV-1) gp120 peptides in HIV-1-infected individuals immunized with HIV-1 rgp120 or rgp160 compared with nonimmunized and uninfected controls.
Sitz KV, Ratto-Kim S, Hodgkins AS, Robb ML, Birx DL.
J Infect Dis. 1999 Apr;179(4):817-24.
Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection.
Flynn NM, Forthal DN, Harro CD, Judson FN, Mayer KH, Para MF; rgp120 HIV Vaccine Study Group.
J Infect Dis. 2005 Mar 1;191(5):654-65. Epub 2005 Jan 27.
Safety and immunogenicity of a high-titered canarypox vaccine in combination with rgp120 in a diverse population of HIV-1-uninfected adults: AIDS Vaccine Evaluation Group Protocol 022A.
Gupta K, Hudgens M, Corey L, McElrath MJ, Weinhold K, Montefiori DC, Gorse GJ, Frey SE, Keefer MC, Evans TG, Dolin R, Schwartz DH, Harro C, Graham B, Spearman PW, Mulligan M, Goepfert P; AIDS Vaccine Evaluation Group.
J Acquir Immune Defic Syndr. 2002 Mar 1;29(3):254-61.
Lessons from a multisite international trial in the Caribbean and South America of an HIV-1 Canarypox vaccine (ALVAC-HIV vCP1452) with or without boosting with MN rgp120.
Cleghorn F, Pape JW, Schechter M, Bartholomew C, Sanchez J, Jack N, Metch BJ, Hansen M, Allen M, Cao H, Montefiori DC, Tomaras GD, Gurunathan S, Eastman DJ, do Lago RF, Jean S, Lama JR, Lawrence DN, Wright PF; 026 Protocol Team and the NIAID HIV Vaccine Trials Network.
J Acquir Immune Defic Syndr. 2007 Oct 1;46(2):222-30.
Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand.
Pitisuttithum P, Gilbert P, Gurwith M, Heyward W, Martin M, van Griensven F, Hu D, Tappero JW, Choopanya K; Bangkok Vaccine Evaluation Group.
J Infect Dis. 2006 Dec 15;194(12):1661-71. Epub 2006 Nov 3.
A novel recombinant bacterial vaccine strain expressing dual viral antigens induces multiple immune responses to the Gag and gp120 proteins of HIV-1 in immunized mice.
Feng Y, Wang S, Luo F, Ruan Y, Kang L, Xiang X, Chao T, Peng G, Zhu C, Mu Y, Zhu Y, Zhang X, Wu J.
Antiviral Res. 2008 Dec;80(3):272-9. Epub 2008 Jul 17.
Recombinant gp120 vaccine-induced antibodies inhibit clinical strains of HIV-1 in the presence of Fc receptor-bearing effector cells and correlate inversely with HIV infection rate.
Forthal DN, Gilbert PB, Landucci G, Phan T.
J Immunol. 2007 May 15;178(10):6596-603.
Controversial HIV vaccine enters phase III trials amid skepticism.
[No authors listed]
AIDS Alert. 1998 Dec;13(12):133-4, 136.
Vaccine to prevent AIDS overstated.
Lewis D.
Res Initiat Treat Action. 1999 Jan;5(1):11-2.
Large-scale HIV vaccine trial to begin this summer.
Highleyman L.
BETA. 1998 Jul:3.
Lessons from failure--preparing for future HIV-1 vaccine efficacy trials.
Graham BS, Mascola JR.
J Infect Dis. 2005 Mar 1;191(5):647-9. Epub 2005 Jan 27. No abstract available.
Phylodynamics of HIV-1 from a phase III AIDS vaccine trial in Bangkok, Thailand.
Pérez-Losada M, Jobes DV, Sinangil F, Crandall KA, Arenas M, Posada D, Berman PW.
PLoS One. 2011 Mar 10;6(3):e16902.
Enrollment of racial/ethnic minorities in NIAID-funded networks of HIV vaccine trials in the United States, 1988 to 2002.
Djomand G, Katzman J, di Tommaso D, Hudgens MG, Counts GW, Koblin BA, Sullivan PS.
Public Health Rep. 2005 Sep-Oct;120(5):543-8.
Mucosal innate immune factors in secretions from high-risk individuals immunized with a bivalent gp120 vaccine.
Cummins JE Jr, Denniston M, Mayer KH, Pickard R, Novak RM, Graham P, Gurwith M, Orelind K, Ackers ML, Dezzutti CS.
AIDS Res Hum Retroviruses. 2007 May;23(5):748-54.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on